Costs of medical care among augmentation therapy users and non-users with alpha-1 antitrypsin deficiency in the United States
Date
2019Journal
Chronic Obstructive Pulmonary DiseasesPublisher
COPD FoundationType
Article
Metadata
Show full item recordAbstract
Background: This study is the first to utilize a large claims database to estimate medical costs of patients with alpha-1 antitrypsin deficiency (AATD) in the United States. Methods: Adult AATD patients were identified from the OptumLabs™ Data Warehouse. Insurer and patient out-of-pocket costs were categorized into the following cost buckets, stratified by augmentation therapy use: physician visits (PV), emergency department visits (ED), inpatient stays (IP), augmentation therapy (AUG), other prescription drug costs (RX), and other costs (OTH). Costs were weighted and adjusted to 2017 U.S. dollars using the medical care component of the consumer price index. Results: The study cohort consisted of 9117 AATD patients followed for 53,872 person years observed between 1993 and 2015. The annual costs among AATD patients totaled $127,537 among augmentation therapy users and $15,874 among non-users. The major drivers of annual costs to the insurer among the 7975 patients not on augmentation therapy were: PV: $5352 (37.7%) and IP: $4506 (31.8%). Among the 1142 augmentation users, major annual cost drivers to the insurer were PV: $15,064 (12.3%) and AUG: $82,002 (66.7%). Annual patient out-of-pocket costs were $4601 (AUG: $2084 [45.3%]; RX: $940 [20.4%]) and $1689 (PV: $727 [43.0%]; RX: $589 [34.9%]) among augmentation therapy users and non-users, respectively. Averaged across the entire cohort, the average annual costs per AATD patient were $22,975, paid by insurers ($21,100) and patients ($1875). Conclusions: Annual medical costs among patients with AATD are $127,537 and $15,874 among augmentation therapy users and non-users, respectively, with 75.3% of the cost difference attributable to AUG. Copyright 2019.Keyword
Alpha-1 antitrypsin deficiencyAugmentation therapy
Chronic obstructive pulmonary disease
Medical costs
Pharmacoeconomics
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064931681&doi=10.15326%2fJCOPDF.6.1.2017.0187&partnerID=40&md5=3b6ffcd1c6401010f8b71e02a7d80764; http://hdl.handle.net/10713/10590ae974a485f413a2113503eed53cd6c53
10.15326/JCOPDF.6.1.2017.0187